Inivata is a leader in liquid biopsy. Our technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and our wider platform, which is applicable to a range of cancer types.

Based in


Created in

> Website


#Healthtech 02.2021


Farallon Capital Management, IP Group PLC, Janus Henderson Investors & Soleus Capital